Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Novo/Schering Prandin Sales Are $35 Mil. Worldwide In 1998

  • News

Executive Summary

Novo Nordisk/Schering's type 2 diabetes therapy Prandin (repaglinide) posted 1998 sales of approximately $35 mil. (DKK 240 mil.), Novo reported Feb. 17.

You may also be interested in...



Novo Nordisk Demerger Expected To Aid External Collaborations

Novo expects the demerger of its healthcare and enzyme businesses in January 2001 to enhance possibilities for collaborations with other companies.

Novo Nordisk Demerger Expected To Aid External Collaborations

Novo expects the demerger of its healthcare and enzyme businesses in January 2001 to enhance possibilities for collaborations with other companies.

Novo's NovoSeven Posts $19 Mil. In U.S. Sales Since April Launch

Novo Nordisk's hemophilia treatment NovoSeven (recombinant Factor VIIa) generated U.S. sales of approximately $19 mil. in its first three months on the U.S. market, Novo indicated in an Aug. 11 statement on half-year financial results. Novo began marketing the product in the U.S. in April.

Table

View full table

Tags:
Latest Headlines

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

Partisan Politics Returns To US FDA Congressional Oversight

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

See All
UsernamePublicRestriction

Register

PS033747

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By